AMGEN Inc (NASDAQ: AMGN)’s stock price has dropped by -1.86 in relation to previous closing price of 295.56. Nevertheless, the company has seen a loss of -1.15% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-14 that Despite the weak performance of Amgen’s rare disease portfolio, it once again beat consensus non-GAAP EPS and revenue estimates. So, the main contributors to strengthening Amgen’s balance sheet and improving its margins in the first quarter of 2025 were Blincyto, Tezspire, Prolia, and Imdelltra. In its oncology franchise, I highlight Imdelltra as the ‘crown jewel,’ with sales of $81 million in the first three months of 2025, up 20.9% quarter-on-quarter.
Is It Worth Investing in AMGEN Inc (NASDAQ: AMGN) Right Now?
The price-to-earnings ratio for AMGEN Inc (NASDAQ: AMGN) is above average at 26.48x. The 36-month beta value for AMGN is also noteworthy at 0.50. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 6 rating it as “overweight,” 15 rating it as “hold,” and 2 rating it as “sell.”
The public float for AMGN is 536.51M, and at present, short sellers hold a 2.41% of that float. The average trading volume of AMGN on June 18, 2025 was 2.97M shares.
AMGN’s Market Performance
AMGN’s stock has seen a -1.15% decrease for the week, with a 6.48% rise in the past month and a -8.98% fall in the past quarter. The volatility ratio for the week is 1.57%, and the volatility levels for the past 30 days are at 1.17% for AMGEN Inc The simple moving average for the last 20 days is 1.50% for AMGN’s stock, with a simple moving average of -2.11% for the last 200 days.
Analysts’ Opinion of AMGN
Many brokerage firms have already submitted their reports for AMGN stocks, with Guggenheim repeating the rating for AMGN by listing it as a “Neutral.” The predicted price for AMGN in the upcoming period, according to Guggenheim is $288 based on the research report published on May 20, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AMGN reach a price target of $305. The rating they have provided for AMGN stocks is “Neutral” according to the report published on April 22nd, 2025.
BofA Securities gave a rating of “Underperform” to AMGN, setting the target price at $256 in the report published on December 10th of the previous year.
AMGN Trading at 2.83% from the 50-Day Moving Average
After a stumble in the market that brought AMGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.38% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMGN starting from Khosla Rachna, who sale 1,500 shares at the price of $289.68 back on Jun 05 ’25. After this action, Khosla Rachna now owns 8,162 shares of AMGEN Inc, valued at $434,520 using the latest closing price.
Khosla Rachna, the Officer of AMGEN Inc, proposed sale 1,500 shares at $290.00 during a trade that took place back on Jun 05 ’25, which means that Khosla Rachna is holding shares at $435,000 based on the most recent closing price.
Stock Fundamentals for AMGN
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.63 for the gross margin
The net margin for AMGEN Inc stands at 0.17. The total capital return value is set at 0.11. Equity return is now at value 105.67, with 6.51 for asset returns.
Based on AMGEN Inc (AMGN), the company’s capital structure generated 0.9 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 9.24. The interest coverage ratio of the stock is 3.19.
Currently, EBITDA for the company is 13.36 billion with net debt to EBITDA at 3.92. When we switch over and look at the enterprise to sales, we see a ratio of 5.99. The receivables turnover for the company is 4.2for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
In summary, AMGEN Inc (AMGN) has had a mixed performance as of late. Analysts have bearish opinions on the stock, with some viewing it as a “sell” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
